Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection
Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity March 20, 2018 06:00 AM Pacific Daylight Time LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with DestiNA Genomics, a manufacturer of patented reagents for nucleic acid detection.... Read more